An opinion on whether a supplementary protection certificate can be granted to an owner of a drug patent when the marketing authorisation is held by a third party is overdue, lawyers told WIPR.
The UK Competition and Markets Authority has provisionally found that pharmaceutical companies Auden Mckenzie and Waymade engaged in anti-competitive behaviour relating to hydrocortisone tablets.
The US International Trade Commission has begun an investigation into Daewoong Pharmaceuticals of South Korea and California-based Evolus, following a complaint from Allergan.
The patents division of the English High Court has found that a patent owned by Genentech is invalid and denied the biotechnology company’s application for a supplementary protection certificate.
The US Federal Trade Commission concluded a ten-year pay-for-delay suit yesterday, with AbbVie agreeing not to enter certain settlements in patent cases that delay market entry of generic drugs.
The US International Trade Commission has begun an investigation into whether a Danish company’s dental and orthodontic scanners and software infringed an American company’s patents.
Patterson Belknap Webb & Tyler has hired Barbara Mullin, a former lawyer at Akin Gump Strauss Hauer & Feld, as special counsel.
A US judge has ordered Boehringer Ingelheim to release its rollout plans for a biosimilar version of Humira (adalimumab), following a request from AbbVie.
General Electric (GE) will sell its biopharma business, which generated $3 billion in revenues for the conglomerate last year, to Danaher in a $21.4 billion deal.
The US Court of Appeals for the Federal Circuit yesterday rejected the University of Florida’s argument that its sovereign immunity protected a patent from section 101 scrutiny.